Indirect comparisons of second-generation tyrosine kinase inhibitors in CML: case study using baseline population characteristics

Indirect comparisons of second-generation tyrosine kinase inhibitors in CML: case study using baseline population characteristics

Kimbach Tran Carpiuc1, Gianantonio Rosti2, Fausto Castagnetti2, Maarten Treur3, Jennifer Stephens11Pharmerit North America LLC, Bethesda, MD, USA; 2Department of Hematology and Oncology, S Orsola-Malpighi University Hospital, Bologna, Italy; 3Pharmerit Europe, Rotterdam, The NetherlandsAbstract: The...

Full description

Bibliographic Details
Main Authors:	Kimbach Tran Carpiuc, Gianantonio Rosti, Fausto Castagnetti, et al
Format:	Article
Language:	English
Published:	Dove Medical Press 2010-10-01
Series:	OncoTargets and Therapy
Online Access:	http://www.dovepress.com/indirect-comparisons-of-second-generation-tyrosine-kinase-inhibitors-i-a5469

Similar Items

Ponatinib and other CML Tyrosine Kinase Inhibitors in Thrombosis
by: Peng Zeng, et al.
Published: (2020-09-01)

Bcr-Abl Tyrosine Kinase Inhibitors in the Treatment of Pediatric CML
by: Francesca Carofiglio, et al.
Published: (2020-06-01)

Use of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia (CML)
by: C. B. Almeida, et al.
Published: (2016-11-01)

Tyrosine kinase inhibitors therapy related neutropenia and thrombocythopenia correction in CML patients
by: V. A. Shuvaev, et al.
Published: (2014-07-01)

Tyrosine kinase inhibitors therapy related neutropenia and thrombocythopenia correction in CML patients
by: V. A. Shuvaev, et al.
Published: (2014-07-01)

The Role of STAT5 in Tyrosine Kinase Inhibitor (IMATINIB) Resistance in CML Patients
by: Anastasia Putri, et al.
Published: (2019-10-01)

Second-generation inhibitors of Bruton tyrosine kinase
by: Jingjing Wu, et al.
Published: (2016-09-01)

Monitoring the response to tyrosine kinase inhibitor (TKI) treatment in chronic myeloid leukemia (CML)
by: Ibrahim C. Haznedaroglu
Published: (2014-08-01)

MONITORING THE RESPONSE TO TYROSINE KINASE INHIBITOR (TKI) TREATMENT IN CHRONIC MYELOID LEUKEMIA (CML)
by: Ibrahim C. Haznedaroglu
Published: (2013-12-01)

Combination of tyrosine kinase inhibitors and the MCL1 inhibitor S63845 exerts synergistic antitumorigenic effects on CML cells
by: Alena Malyukova, et al.
Published: (2021-09-01)

Discontinuation of tyrosine kinase inhibitors in CML patients in real-world clinical practice at a single institution
by: Nuno Cerveira, et al.
Published: (2018-12-01)

ABCB1 Overexpression Is a Key Initiator of Resistance to Tyrosine Kinase Inhibitors in CML Cell Lines.
by: Laura N Eadie, et al.
Published: (2016-01-01)

Expression of PML Nuclear Bodies Enhanced The CML Cells Growth Inhibitory Ability of Tyrosine Kinase Inhibitor
by: Chen-Jei Hong, et al.
Published: (2001)

Evolution of BCR/ABL gene mutation in CML is time dependent and dependent on the pressure exerted by tyrosine kinase inhibitor.
by: Shantashri Vaidya, et al.
Published: (2015-01-01)

BCR-ABL1 Doubling-Times and Halving-Times May Predict CML Response to Tyrosine Kinase Inhibitors
by: Maria Stella Pennisi, et al.
Published: (2019-08-01)

Treatment Effects of the Second-Generation Tyrosine Kinase Inhibitor Dasatinib on Autoimmune Arthritis
by: Kai Guo, et al.
Published: (2019-01-01)

Sequential Use of Second-Generation Tyrosine Kinase Inhibitor Treatment and Intensive Chemotherapy Induced Long-Term Complete Molecular Response in Imatinib-Resistant CML Patient Presenting as a Myeloid Blast Crisis
by: Masaaki Tsuji, et al.
Published: (2017-01-01)

Varying effects of tyrosine kinase inhibitors on platelet function—A need for individualized CML treatment to minimize the risk for hemostatic and thrombotic complications?
by: Suryyani Deb, et al.
Published: (2020-01-01)

A novel oncogene AHI-1 interacts with BCR-ABL and JAK2 and mediates cellular resistance to tyrosine kinase inhibitors in CML
by: DeGeer, Donna
Published: (2010)

A novel oncogene AHI-1 interacts with BCR-ABL and JAK2 and mediates cellular resistance to tyrosine kinase inhibitors in CML
by: DeGeer, Donna
Published: (2010)

A novel oncogene AHI-1 interacts with BCR-ABL and JAK2 and mediates cellular resistance to tyrosine kinase inhibitors in CML
by: DeGeer, Donna
Published: (2010)

The role of second generation Bruton tyrosine kinase inhibitors in the treatment of chronic lymphocytic leukemia. Resolution
by: Irina V. Poddubnaya, et al.
Published: (2020-05-01)

The burden of managing pleural effusions in patients with chronic myelogenous leukemia post-imatinib failure: A literature-based economic analysis
by: Jennifer Stephens, et al.
Published: (2009-12-01)

Dosing Strategies for Improving the Risk-Benefit Profile of Ponatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase
by: Fausto Castagnetti, et al.
Published: (2021-03-01)

Mild clinical course of COVID-19 infection in chronic myeloid leukemia (CML) patients receiving tyrosine kinase inhibitors (TKIs) without interruption
by: Judit Demeter, et al.
Published: (2021-02-01)

Current Treatment Options for Chronic Myeloid Leukemia Patients Failing Second-Generation Tyrosine Kinase Inhibitors
by: Valentín García-Gutiérrez, et al.
Published: (2020-07-01)

Arterial Events in Patients with Chronic Myeloid Leukemia Receiving Treatment with Second Generation Tyrosine Kinase Inhibitors
by: GA Gusarova, et al.
Published: (2016-10-01)

SECOND-GENERATION TYROSINE KINASE INHIBITORS (TKI) AS SALVAGE THERAPY FOR RESISTANT OR INTOLERANT PATIENTS TO PRIOR TKIs
by: Massimo Breccia, et al.
Published: (2014-01-01)

Hyper-activation of Aurora kinase a-polo-like kinase 1-FOXM1 axis promotes chronic myeloid leukemia resistance to tyrosine kinase inhibitors
by: M. Mancini, et al.
Published: (2019-05-01)

Intracellular retention of ABL kinase inhibitors determines commitment to apoptosis in CML cells.
by: Daniel B Lipka, et al.
Published: (2012-01-01)

Exosomes from Bone Marrow Microenvironment-Derived Mesenchymal Stem Cells Affect CML Cells Growth and Promote Drug Resistance to Tyrosine Kinase Inhibitors
by: Xiaoyan Zhang, et al.
Published: (2020-01-01)

Dual EGFR and ABL Tyrosine Kinase Inhibitor Treatment in a Patient with Concomitant EGFR-Mutated Lung Adenocarcinoma and BCR-ABL1-Positive CML
by: Kousuke Watanabe, et al.
Published: (2020-01-01)

Afatinib: emerging next-generation tyrosine kinase inhibitor for NSCLC
by: Nelson V, et al.
Published: (2013-03-01)

TYROSINE KINASE INHIBITORS AND PREGNANCY
by: Elisabetta Abruzzese, et al.
Published: (2014-04-01)

TYROSINE KINASE INHIBITORS AND INTERFERON
by: Maria Dimou, et al.
Published: (2014-01-01)

Cardiovascular and metabolic problems associated with application of second generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia
by: O. Y. Vinogradova
Published: (2015-10-01)

TREATMENT RECOMMENDATIONS FOR CHRONIC MYELOID LEUKEMIA
by: Michele Baccarani, et al.
Published: (2014-01-01)

Design and Discovery of 3rd Generation EGFR Tyrosine Kinase Inhibitors
by: Hsueh, Chin, et al.
Published: (2018)

Tyrosine kinase inhibitors in hematological malignancies
by: Kamila Kosior, et al.
Published: (2011-12-01)

Synthesis of new tyrosine kinase inhibitors
by: Sørum, Christopher
Published: (2009)

Cannot write session to /tmp/vufind_sessions/sess_tn2bpgoldrf61j6lud8nu7fthn